GoldenGolden
Advanced Search
Insilico Medicine

Insilico Medicine

Insilico Medicine is a drug discovery, artificial intelligence company that looks to treat cancer and age related diseases

Insilico Medicine is a drug discovery, artificial intelligence company that looks to treat cancer and age related diseases. The company was founded by Alex Zhavoronkov in 2014, in Rockville, Maryland, United States.

The company looks to extend deep learning and artificial intelligence solutions for drug and aging research. The company provides 3D molecular representations based on the wave transform for Convolution Neural Networks Molecular pharmaceutics. Insilico Medicine's drug discovery engine utilizes millions of samples and multiple data types to discover signatures of disease and to identify targets for molecules that exist or can be generated.

The company looks to launch research and development centers and research results in Taiwan. Their team consists of scientists that operate in the United States, United Kingdom, Poland, Belgium, South Korea, Taiwan, Africa, and Russia.

COVID-19

In response to the outbreak of coronavirus (COVID-19), the company has offered support to discover drugs. They have been working on research with six molecules to combat the virus. Insilico Medicine is using their AI-based drug discovery pipeline to identify drug molecules that could target 3C-like protease. 3C-like protease is a SARS-CoV-2 protein that is a target for potential drugs because it has a central role in the viral replication cycle. A portion will be tested by Insilico Medicine and the remainder of the potentially useful structures will be published on the company website and available to the public (https://insilico.com/ncov-sprint/).

Timeline

June 22, 2021
Insilico Medicine raises $255,000,000 in a Series C funding round led by Warburg Pincus .
February 22, 2021
Insilico Medicine appoints of Dr. Feng Ren as Chief Science Officer ("CSO").

December 29, 2020
Insilico Medicine enters into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology.

Funding rounds

Patents

Products

People

Name
Role
LinkedIn

Alex Aliper

Employee

Alex Zhavoronkov

Founder

Alexander H. Perkins

Employee

Artem V. Artemov

Employee

Eli Mohamad

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Insilico Medicine

Alex Zhavoronkov

Rockville, Maryland, United States

Medical products, DNA

News

Title
Author
Date
Publisher
Description
Andrea Park
August 27, 2021
FierceBiotech
After proving the abilities of its AI drug discovery platform with the rapid development of drug candidates in fibrosis, Insilico Medicine is taking its talents to the realm of incurable diseases.
Conor Hale
August 4, 2021
FierceBiotech
Earlier this year, Insilico Medicine demonstrated its artificial intelligence programs could identify a new disease target, design a new drug and prepare it for clinical trials, all within 18 months at a total price tag of less than $3 million. Now, it's done it again.
Conor Hale
June 22, 2021
FierceBiotech
Insilico Medicine netted $255 million in its third investment round--a big step up from the $37 million it raised in 2019--reflecting what it's achieved in the intervening years.
Emma Betuel
June 22, 2021
TechCrunch
Insilico Medicine, an A.I-based platform for drug development and discovery announced $255 million in Series C financing on Tuesday. The massive round is reflective of a recent breakthrough for the company: proof that it's A.I based platform can create a new target for a disease, develop a bespoke molecule to address it, and begin the [...]
FinSMEs
June 22, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.